The effect of human myelomonocytic leukemic cell line (m20) derived IL-1 inhibitor on human erythroid cell development

Eitan Fibach, Michal Rigel, Tony Peled, Abraham J. Treves, Vivian Barak

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    The effect of an inhibitor of IL-1, purified from a human myelomonocytic cell line (M20) on the development of human erythroid cell development was studied. The inhibitor, is a protein of 52 kD molecular weight that is distinct immunologically and functionally from other reported IL-1 inhibitors. The experiments were performed in a two-phase culture system that allows separation of the erythroid cell development into an erythropoietin (EPO)-independent phase, where early erythroid-committed BFUe proliferate and differentiate into the more mature progenitors, CFUe, and EPO-dependent phase, where CFUe further proliferate and mature into hemoglobin-containing orthochromatic normoblasts. The results indicated that in both developmental stages the M20-derived inhibitor reversibly blocked cell proliferation without interfering with cell differentiation.

    Original languageEnglish (US)
    Pages (from-to)327-332
    Number of pages6
    JournalLeukemia and Lymphoma
    Volume15
    Issue number3-4
    DOIs
    StatePublished - Jan 1 1994

    Keywords

    • Cell proliferation
    • Cytokines
    • Differentiation
    • Erythroid progenitors
    • Interleukin-1
    • Interleukin-1 inhibitor

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'The effect of human myelomonocytic leukemic cell line (m20) derived IL-1 inhibitor on human erythroid cell development'. Together they form a unique fingerprint.

  • Cite this